- Major tech companies like Microsoft, Google, Amazon, and OpenAI are heavily investing in and competing within the AI revolution.
- Major tech companies like Microsoft, Google, Amazon, and OpenAI are heavily investing in and competing within the AI revolution.
- Trump-era tariffs may benefit AI stocks, while Google faces DOJ rulings and secures a default search engine deal with Apple.
- Amid ongoing Russia/Ukraine conflict, a confluence of events occurred on September 2, 2025, including a tariffs ruling affecting the bond market and an MIT report on failing AI projects.
BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.
4 reports, 2 independent
Updated Jun 14
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Trump-era tariffs are cited as benefiting AI stocks like Nvidia.1 source
BioCryst Pharmaceuticals is cited as benefiting from the Trump-era tariffs ruling.1 source
BioMarin benefits from AI stock gains due to Trump-era tariffs.1 source
Keep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
BioCryst Pharmaceuticals
American pharmaceutical company
-
BioMarin Pharmaceutical
American company
Related events
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
- Trump-era tariffs are reportedly benefiting certain AI stocks, with the entities Trump and Bank of NT Butterfield & Son involved.
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Trump's policies, including tariffs and onshoring, are being discussed in the context of their potential benefits for AI stocks, with specific attention paid to Moderna's performance and guidance.
Coverage
Newest first; wire copies grouped- yahoo.com
- yahoo.com
- Insider MonkeyBioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. BioCr
- Insider MonkeyWhat Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy growth stocks to buy now. On August 19, Bernstein analyst Wi